I
Irving D. Kaplan
Researcher at Beth Israel Deaconess Medical Center
Publications - 192
Citations - 15404
Irving D. Kaplan is an academic researcher from Beth Israel Deaconess Medical Center. The author has contributed to research in topics: Prostate cancer & Radiation therapy. The author has an hindex of 44, co-authored 174 publications receiving 14327 citations. Previous affiliations of Irving D. Kaplan include Brigham and Women's Hospital & Beth Israel Deaconess Hospital.
Papers
More filters
Journal ArticleDOI
Biochemical Outcome after radical prostatectomy, external beam Radiation Therapy, or interstitial Radiation therapy for clinically localized prostate cancer
Anthony V. D'Amico,R. Whittington,S.B. Malkowicz,Daniel Schultz,Kenneth R. Blank,Gregory A. Broderick,John E. Tomaszewski,Andrew A. Renshaw,Irving D. Kaplan,Clair J. Beard,Alan J. Wein +10 more
TL;DR: Low-risk patients had estimates of 5-year PSA outcome after treatment with RP, RT, or implant with or without neoadjuvant androgen deprivation that were not statistically different, whereas intermediate- and high- risk patients treated with RP or RT did better then those treated by implant.
Journal ArticleDOI
Quality of life and satisfaction with outcome among prostate-cancer survivors.
Martin G. Sanda,Rodney L. Dunn,Jeff M. Michalski,Howard M. Sandler,Laurel L. Northouse,Larry Hembroff,Xihong Lin,Thomas K. Greenfield,Mark S. Litwin,Mark S. Litwin,Christopher S. Saigal,Arul Mahadevan,Eric A. Klein,Adam S. Kibel,Louis L. Pisters,Deborah A. Kuban,Irving D. Kaplan,Darien Wood,Jay P. Ciezki,Nikhil L. Shah,John T. Wei +20 more
TL;DR: Each prostate-cancer treatment was associated with a distinct pattern of change in quality-of-life domains related to urinary, sexual, bowel, and hormonal function, and these changes influenced satisfaction with treatment outcomes among patients and their spouses or partners.
Journal ArticleDOI
Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer
Anthony V. D'Amico,R. Whittington,S.B. Malkowicz,Daniel Schultz,Kenneth R. Blank,Gregory A. Broderick,John E. Tomaszewski,Andrew A. Renshaw,Irving D. Kaplan,Clair J. Beard,Alan J. Wein +10 more
TL;DR: Low-risk patients had estimates of 5-year PSA outcome after treatment with RP, RT, or implant with or without neoadjuvant androgen deprivation that were not statistically different, whereas intermediate- and high- risk patients treated with RP or RT did better then those treated by implant.
Journal Article
Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage.
Máirín E. McMenamin,Peggy Soung,Sauni P. Perera,Irving D. Kaplan,Massimo Loda,William R. Sellers +5 more
TL;DR: Loss of PTEN protein is correlated with pathological markers of poor prognosis in prostate cancer and correlated more significantly with a Gleason score of 7 or higher and with advanced pathological stage.
Journal ArticleDOI
Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials
Christopher R. King,Debra Freeman,Irving D. Kaplan,Donald B. Fuller,Giampaolo Bolzicco,Sean P. Collins,Robert J. Meier,Jason Wang,Patrick A. Kupelian,Michael L. Steinberg,Alan W. Katz +10 more
TL;DR: PSA relapse-free survival rates after SBRT compare favorably with other definitive treatments for low and intermediate risk patients, and the current evidence supports consideration of S BRT among the therapeutic options for these patients.